Health Care • Biotechnology: Pharmaceutical Preparations
$146.33 ▲ +5.40
(+3.83%)
MKT CAP: $361.02B • VOL: 13.45M
52W L $82 52W H $157
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$123
MEDIAN
$164
MEAN
$167
HIGH
$199
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MRK TAPE
MRK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $177.06 | $168.28 | 2025-02-14 | $133.16 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $184.38 | $172.67 | 2025-02-06 | $137.55 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $166.82 | $160.96 | 2025-01-29 | $140.48 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $149.26 | — | 2025-01-17 | $143.40 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $128.77 | $139.01 | 2025-01-09 | $130.23 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $174.13 | $152.18 | 2024-12-18 | $127.31 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $141.94 | $147.79 | 2024-12-04 | $136.09 | -4.3% | 48% | C |